3-D deconvolution of hyper-spectral astronomical data

In this paper we present a general forward fitting method for multichannel image restoration based on regularized chi2. We introduce separable regularizations that account for the dynamic of the model and take advantage of the continuities present in the data, leaving only two hyper-parameters to tune. We illustrate a practical implementation of this method in the context of host galaxy subtraction for the Nearby SuperNova factory. We show that the image restoration obtained fulfills the stringent requirements on bias and photometricity needed by this program. The reconstruction yields sub-percent integrated residuals in all the synthetic filters considered both on real and simulated data. Even though our implementation is tied to the SNfactory data, the method translates to any hyper-spectral data. As such, it is of direct relevance to several new generation instruments like MUSE. Also, this technique could be applied to multi-band astronomical imaging for which image reconstruction is important, for example to increase image resolution for weak lensing surveys.Comment: 14 pages, 12 figures, 3 tables. Accepted for publication in MNRA

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE: To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea. The trial was terminated based on the results of this planned interim analysis. INTERVENTIONS: Treatment with TTFields was delivered continuously (>18 hours/day) via 4 transducer arrays placed on the shaved scalp and connected to a portable medical device. Temozolomide (150-200 mg/m2/d) was given for 5 days of each 28-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival in the intent-to-treat population (significance threshold of .01) with overall survival in the per-protocol population (n = 280) as a powered secondary end point (significance threshold of .006). This prespecified interim analysis was to be conducted on the first 315 patients after at least 18 months of follow-up. RESULTS: The interim analysis included 210 patients randomized to TTFields plus temozolomide and 105 randomized to temozolomide alone, and was conducted at a median follow-up of 38 months (range, 18-60 months). Median progression-free survival in the intent-to-treat population was 7.1 months (95% CI, 5.9-8.2 months) in the TTFields plus temozolomide group and 4.0 months (95% CI, 3.3-5.2 months) in the temozolomide alone group (hazard ratio [HR], 0.62 [98.7% CI, 0.43-0.89]; P = .001). Median overall survival in the per-protocol population was 20.5 months (95% CI, 16.7-25.0 months) in the TTFields plus temozolomide group (n = 196) and 15.6 months (95% CI, 13.3-19.1 months) in the temozolomide alone group (n = 84) (HR, 0.64 [99.4% CI, 0.42-0.98]; P = .004). CONCLUSIONS AND RELEVANCE: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00916409

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial

Importance Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. Design, Setting, and Participants This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy. Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide alone. The study was conducted from July 2009 until November 2014, and patients were followed up through December 2016. Interventions Temozolomide, 150 to 200 mg/m2/d, was given for 5 days during each 28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed on the shaved scalp of patients and were connected to a portable medical device. Main Outcomes and Measures Primary study end point was progression-free survival; HRQoL was a predefined secondary end point, measured with questionnaires at baseline and every 3 months thereafter. Mean changes from baseline scores were evaluated, as well as scores over time. Deterioration-free survival and time to deterioration were assessed for each of 9 preselected scales and items. Results Of the 695 patients in the study, 639 (91.9%) completed the baseline HRQoL questionnaire. Of these patients, 437 (68.4%) were men; mean (SD) age, 54.8 (11.5) years. Health-related quality of life did not differ significantly between treatment arms except for itchy skin. Deterioration-free survival was significantly longer with TTFields for global health (4.8 vs 3.3 months; P < .01); physical (5.1 vs 3.7 months; P < .01) and emotional functioning (5.3 vs 3.9 months; P < .01); pain (5.6 vs 3.6 months; P < .01); and leg weakness (5.6 vs 3.9 months; P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting the influence of treatment, did not differ significantly except for itchy skin (TTFields worse; 8.2 vs 14.4 months; P < .001) and pain (TTFields improved; 13.4 vs 12.1 months; P < .01). Role, social, and physical functioning were not affected by TTFields. Conclusions and Relevance The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays. Trial Registration clinicaltrials.gov Identifier: NCT00916409

Velocity distributions of sputtered excited atoms

The first direct measurements are reported of the velocity distributions of sputtered atoms in excited states with electronic configurations completely different from the ground state. In contrast to previous work, the measured distributions for both the singlet and triplet metastable D states of Ba atoms showed no energy thresholds and had most probable energies similar to those of sputtered ground-state atoms.Peer reviewedElectrical and Computer Engineerin

Simultaneous super-resolution and blind deconvolution

In many real applications, blur in input low-resolution images is a nuisance, which prevents traditional super-resolution methods from working correctly. This paper presents a unifying approach to the blind deconvolution and superresolution problem of multiple degraded low-resolution frames of the original scene. We introduce a method which assumes no prior information about the shape of degradation blurs and which is properly defined for any rational (fractional) resolution factor. The method minimizes a regularized energy function with respect to the high-resolution image and blurs, where regularization is carried out in both the image and blur domains. The blur regularization is based on a generalized multichannel blind deconvolution constraint. Experiments on real data illustrate robustness and utilization of the method. © 2008 IOP Publishing LtdThis work has been partially supported by the projects TEC 2004-00834, TEC2005-24739-E, TEC2005-24046-E, PI040765, 2004CZ0009 CSIC-Academy of Sciences of the Czech Republic, No. 202/05/0242 of the Grant Agency of the Czech Republic and No. 1M0572 (Research Center DAR) of the Czech Ministry of Education.Peer Reviewe

Formation of excited Ag atoms in sputtering of silver

A model is presented for the formation of excited Ag* (4d 9 5s 2 ) atoms during sputtering of Ag metal by energetic Ar ϩ ions. The essential part of the formation process is the slow diffusion of 4d holes in the collision cascade from the sites of violent Ag-Ag collisions to the emitted Ag atoms. A computer simulation of Ag cascades and of the 4d-hole transport allows us to quantify the model and to describe all characteristic features of the available experimental data, in particular the fact that the sputtered Ag* atoms exhibit a narrower kinetic energy distribution than those ejected in the electronic ground state